Search Results for "Risperdal"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Risperdal. Results 11 to 20 of 29 total matches.
See also: risperidone
In Brief: Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
months5 11,760.30
Risperidone – Risperdal Consta 12.5, 25, 37.5, 50 mg vials 25, 37.5, or 50 mg IM q2 ...
Invega Hafyera (Janssen), a long-acting, extended-release
(ER) formulation of the second-generation
antipsychotic paliperidone palmitate, has been
approved by the FDA for twice-yearly IM treatment
of schizophrenia in adults who have been adequately
treated with another injectable ER formulation of the
drug (Invega Sustenna or Invega Trinza). It is the first
drug to become available in the US for twice-yearly
treatment of schizophrenia.
In Brief: Injectable Paliperidone Palmitate for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
Paliperidone is the primary active metabolite of risperidone (Risperdal),
which is also available as a long ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
Triptorelin (Triptodur) for Central Precocious Puberty
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
have occurred.
DRUG INTERACTIONS — Hyperprolactinemic drugs,
such as phenothiazines, risperidone (Risperdal ...
The FDA has approved an extended-release
intramuscular suspension formulation of the
gonadotropin-releasing hormone (GnRH) agonist
triptorelin (Triptodur – Arbor/Debiopharm) for twice-yearly
treatment of central precocious puberty (CPP)
in children ≥2 years old. Triptorelin has been available
in the US for years as Trelstar for palliative treatment
of advanced prostate cancer. Before the approval
of Triptodur, Trelstar was used off-label for treatment of CPP.
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
–
Risperdal Consta (Janssen) 12.5, 25, 37.5, 50 mg vials 25, 37.5, or 50 mg IM q2 weeks8 1229.10
Rykindo ...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).
Med Lett Drugs Ther. 2023 Dec 25;65(1692):207-8 doi:10.58347/tml.2023.1692d | Show Introduction Hide Introduction
Extended-Release Carbamazepine (Equetro) for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005 (Issue 1205)
Sedation, hyponatremia
Trileptal divided bid 184.50
Risperidone – Risperdal Acute mania/mixed 1-6 mg once ...
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro, for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
Brexpiprazole (Rexulti) for Schizophrenia and Depression
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
, 4, mg tabs; 4-8 mg/d in 1 or 2 mg/d in 1 or 25.60
Risperdal (Janssen) 1 mg/mL soln 2 doses 2 doses7 ...
The FDA has approved the oral, once-daily, second-generation
antipsychotic brexpiprazole (Rexulti –
Otsuka/Lundbeck) for treatment of schizophrenia
and as an adjunct to antidepressants for treatment
of major depressive disorder (MDD). Aripiprazole
(Abilify), a structurally similar second-generation
antipsychotic also comarketed by Otsuka (with BMS),
recently became available generically.
Two Long-Acting Injectable Antipsychotics for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015 (Issue 1481)
, 37.5, 50 mg vials 25 mg IM q2 weeks 723.70
Risperdal Consta (Janssen)
IM = intramuscular; SC ...
The FDA has approved two new long-acting injectable
formulations of second-generation antipsychotics
for treatment of schizophrenia: aripiprazole lauroxil
(Aristada – Alkermes), which is given once every 4-6
weeks, and paliperidone palmitate (Invega Trinza –
Janssen), which is given once every 3 months.
Once-monthly injectable formulations of aripiprazole
(Abilify Maintena) and paliperidone palmitate (Invega
Sustenna) were approved earlier.
Ziprasidone (Geodon) For Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001 (Issue 1106)
Risperidone − Risperdal (Janssen) 3 mg bid or 6 mg once daily 313.42
Ziprasidone − Geodon (Pfizer) 20 mg bid ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Aripiprazole (Abilify) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003 (Issue 1150)
Quetiapine − Seroquel (AstraZeneca) 250 mg bid 486.00
Risperidone − Risperdal (Janssen) 4 mg once daily ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
AmpliChip CYP450 Test
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
)
aripiprazole (Abilify) phenytoin (Dilantin)
haloperidol (Haldol) voriconazole (Vfend)
risperidone (Risperdal ...
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.